183 related articles for article (PubMed ID: 36208441)
1. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
2. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
[TBL] [Abstract][Full Text] [Related]
3. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
4. Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines.
Jeong H; Jo Y; Yoon M; Hong S
Genes Genomics; 2021 Sep; 43(9):995-1001. PubMed ID: 33950471
[TBL] [Abstract][Full Text] [Related]
5. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
6. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
7. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
Chang E; Pohling C; Beygui N; Patel CB; Rosenberg J; Ha DH; Gambhir SS
J Neurooncol; 2017 Sep; 134(2):259-268. PubMed ID: 28681243
[TBL] [Abstract][Full Text] [Related]
9. Theory and application of TTFields in newly diagnosed glioblastoma.
Yu A; Zeng J; Yu J; Cao S; Li A
CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
[TBL] [Abstract][Full Text] [Related]
10. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
11. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
12. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
Elife; 2023 Nov; 12():. PubMed ID: 37955637
[TBL] [Abstract][Full Text] [Related]
13. Tumor treating fields: concept, evidence and future.
Pless M; Weinberg U
Expert Opin Investig Drugs; 2011 Aug; 20(8):1099-106. PubMed ID: 21548832
[TBL] [Abstract][Full Text] [Related]
14. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics.
Voloshin T; Schneiderman RS; Volodin A; Shamir RR; Kaynan N; Zeevi E; Koren L; Klein-Goldberg A; Paz R; Giladi M; Bomzon Z; Weinberg U; Palti Y
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080774
[TBL] [Abstract][Full Text] [Related]
15. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
16. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
Riley MM; San P; Lok E; Swanson KD; Wong ET
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
[TBL] [Abstract][Full Text] [Related]
18. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
Karanam NK; Ding L; Aroumougame A; Story MD
Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
[TBL] [Abstract][Full Text] [Related]
19. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
20. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
